MCID: FML125
MIFTS: 19

Familial Hodgkin Disease

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Familial Hodgkin Disease

MalaCards integrated aliases for Familial Hodgkin Disease:

Name: Familial Hodgkin Disease 24
Hodgkin's Lymphoma, Familial 24
Hodgkin's Disease, Familial 24
Hodgkin Lymphoma, Familial 24
Familial Hodgkin Lymphoma 24
Hodgkin Disease, Familial 24

Classifications:



Summaries for Familial Hodgkin Disease

MalaCards based summary : Familial Hodgkin Disease, also known as hodgkin's lymphoma, familial, is related to lymphoma, non-hodgkin and hodgkin lymphoma. An important gene associated with Familial Hodgkin Disease is COLQ (Collagen Like Tail Subunit Of Asymmetric Acetylcholinesterase). The drugs Bleomycin and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and b cells.

Related Diseases for Familial Hodgkin Disease

Diseases related to Familial Hodgkin Disease via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin 11.1
2 hodgkin lymphoma 9.7
3 nodular lymphocyte predominant hodgkin lymphoma 9.6

Symptoms & Phenotypes for Familial Hodgkin Disease

Drugs & Therapeutics for Familial Hodgkin Disease

Drugs for Familial Hodgkin Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved Phase 3,Phase 2 11056-06-7 5360373
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
3
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Mechlorethamine Approved Phase 3,Phase 2 51-75-2 4033
7
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
9
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
11
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
13
Benzocaine Approved Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
14
Tacrolimus Approved, Investigational Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
15 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Imidazole Experimental Phase 3 288-32-4 795
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Antirheumatic Agents Phase 3,Phase 2,Phase 1
26 Dermatologic Agents Phase 3,Phase 2
27 Etoposide phosphate Phase 3,Phase 2,Phase 1
28 glucocorticoids Phase 3,Phase 1,Phase 2
29 Hormone Antagonists Phase 3,Phase 1,Phase 2
30 Hormones Phase 3,Phase 1,Phase 2
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Keratolytic Agents Phase 3,Phase 2
34 Nitrogen Mustard Compounds Phase 3,Phase 2
35 Podophyllotoxin Phase 3,Phase 2 518-28-5
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
37 Cyclosporins Phase 3,Phase 2
38
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
39
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
40
Vidarabine Approved Phase 1, Phase 2 24356-66-9 32326 21704
41
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
42
rituximab Approved Phase 2 174722-31-7 10201696
43 Thiotepa Approved Phase 2,Phase 1 52-24-4 5453
44
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
45
Carmustine Approved Phase 2 154-93-8 2578
46
Mesna Approved Phase 2 3375-50-6 598
47
Methylprednisolone Approved, Vet_approved Phase 2,Phase 1 83-43-2 6741
48
Prednisolone Approved, Vet_approved Phase 2,Phase 1 50-24-8 5755
49
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
50
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show all 36)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Unknown status NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
2 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
3 Double Cord Versus Haploidentical (BMT CTN 1101) Recruiting NCT01597778 Phase 3
4 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
5 Autologous and Allogeneic Transplant for Relapsed Lymphoma Completed NCT00802113 Phase 1, Phase 2 Fludarabine and Busulfan;Fludarabine, Busulfan and ATG
6 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Completed NCT00359892 Phase 2 Obatoclax mesylate (GX15-070MS)
7 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
8 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
9 Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases Completed NCT00056966 Phase 1, Phase 2 ANTI-CD45;CAMPATH-1H;FK506;Fludarabine
10 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
11 Study of @neWorld: A Virtual Community for Children With Cancer Completed NCT00070421 Phase 1, Phase 2
12 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor Completed NCT01696461 Phase 2 Plerixafor
13 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00002941 Phase 2 carmustine;cyclophosphamide;etoposide;mesna
14 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
15 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
16 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
17 MSC and HSC Coinfusion in Mismatched Minitransplants Recruiting NCT01045382 Phase 2
18 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Recruiting NCT02061800 Phase 1, Phase 2 Thiotepa;Cyclophosphamide;Alemtuzumab;Tacrolimus;Melphalan;Busulfan;Fludarabine;Methylprednisolone
19 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Active, not recruiting NCT00566696 Phase 2 Fludarabine;Thioplex®;L-phenylalanine mustard;Mycophenolate mofetil;Rituxan™;Alemtuzumab;Cyclophosphamide;Anti-thymocyte globulin (Rabbit);G-CSF;Muromonab
20 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00822120 Phase 2 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
21 Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Terminated NCT01390584 Phase 2 ABVD Induction;Escalated BEACOPP;Standard BEACOPP
22 Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies Terminated NCT01745913 Phase 2 Fludarabine;Melphalan;Rabbit ATG
23 Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant Completed NCT00569283 Phase 1
24 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Completed NCT00304018 Phase 1 busulfan;etoposide;fludarabine phosphate;prednisone;tacrolimus
25 SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma Completed NCT00293488 Phase 1 polyamine analogue PG11047
26 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1 dexrazoxane hydrochloride;doxorubicin hydrochloride;obatoclax mesylate;liposomal vincristine sulfate
27 Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease Completed NCT00521430 busulfan;cyclosporine;fludarabine phosphate;methotrexate;methylprednisolone
28 Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Completed NCT00981097
29 Genetic Study of Families With High Frequency of Hodgkin Lymphoma Recruiting NCT02795013
30 Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders Recruiting NCT00582621
31 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Recruiting NCT00131014
32 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer Recruiting NCT00039676
33 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
34 Study of Lymphoma in Asia Recruiting NCT01584141
35 Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment Recruiting NCT01790152
36 Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer Terminated NCT00301860 cyclosporine;fludarabine phosphate;melphalan;methotrexate

Search NIH Clinical Center for Familial Hodgkin Disease

Genetic Tests for Familial Hodgkin Disease

Genetic tests related to Familial Hodgkin Disease:

id Genetic test Affiliating Genes
1 Familial Hodgkin Disease 24

Anatomical Context for Familial Hodgkin Disease

MalaCards organs/tissues related to Familial Hodgkin Disease:

39
Bone Marrow, Bone, B Cells, Heart, Liver

Publications for Familial Hodgkin Disease

Articles related to Familial Hodgkin Disease:

id Title Authors Year
1
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. ( 11781255 )
2002
2
Letter: Familial Hodgkin disease. ( 4479174 )
1974

Variations for Familial Hodgkin Disease

Expression for Familial Hodgkin Disease

Search GEO for disease gene expression data for Familial Hodgkin Disease.

Pathways for Familial Hodgkin Disease

GO Terms for Familial Hodgkin Disease

Sources for Familial Hodgkin Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....